Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study
- 1 April 2018
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 181 (2), 259-261
- https://doi.org/10.1111/bjh.14540
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2015
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaThe New England Journal of Medicine, 2013
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell MalignanciesJournal of Clinical Oncology, 2013
- Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2012
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- 7 The Log-Rank or Mantel-Haenszel Test for the Comparison of Survival CurvesPublished by S. Karger AG ,2007
- Statistics Notes: Survival probabilities (the Kaplan-Meier method)BMJ, 1998